Data suggest that CD19-directed CAR T-cell therapy may be curative for patients with relapsed or refractory CLL who maintain a response for at least 1 year.

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Paclitaxel-based and nab-paclitaxel-based chemotherapy produced similar 5-year outcomes in patients with high-risk, HR+, HER2- early breast cancer.

The approval was based on data from a single-arm, phase 3 trial. The US Food and Drug Administration (FDA) has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft ...

Disease-free and overall survival outcomes were similar across dosing schedules. Patients with high-risk early breast cancer have similar survival outcomes with different dosing schedules of ...

Source: Getty Images Brain tumors are one of the most common tumors found in pediatric patients. Diffuse intrinsic pontine glioma accounts for 15% to 20% of all childhood brain tumors and ...

There is no indication that Luigi Mangione, the man charged with killing UnitedHealthcare CEO Brian Thompson, was ever a client of UnitedHealthcare, according to authorities.

Though lung cancer survival rates are improving, lung cancer is still the leading cause of cancer deaths in the US.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.